Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 심기남 | * |
dc.date.accessioned | 2018-12-07T16:30:52Z | - |
dc.date.available | 2018-12-07T16:30:52Z | - |
dc.date.issued | 2017 | * |
dc.identifier.issn | 1976-2283 | * |
dc.identifier.other | OAK-20482 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/247454 | - |
dc.description.abstract | Background/Aims: The resistance rate of Helicobacter pylori is gradually increasing. We aimed to evaluate the efficacy of levofloxacin-based third-line H. pylori eradication in peptic ulcer disease. Methods: Between 2002 and 2014, 110 patients in 14 medical centers received levofloxacin-based third-line H. pylori eradication therapy for peptic ulcer disease. Of these, 88 were included in the study; 21 were excluded because of lack of follow-up and one was excluded for poor compliance. Their eradication rates, treatment regimens and durations, and types of peptic ulcers were analyzed. Results: The overall eradiation rate was 71.6%. The adherence rate was 80.0%. All except one received a protonpump inhibitor, amoxicillin, and levofloxacin. One received a proton-pump inhibitor, amoxicillin, levofloxacin, and clarithromycin, and the eradication was successful. Thirty-one were administered the therapy for 7 days, 25 for 10 days, and 32 for 14 days. No significant differences were observed in the eradication rates between the three groups (7-days, 80.6% vs 10-days, 64.0% vs 14-days, 68.8%, p=0.353). Additionally, no differences were found in the eradiation rates according to the type of peptic ulcer (gastric ulcer, 73.2% vs duodenal/ gastroduodenal ulcer, 68.8%, p=0.655). Conclusions: Levofloxacin-based third-line H. pylori eradication showed efficacy similar to that of previously reported first/second-line therapies. | * |
dc.description.sponsorship | Ministry of Food and Drug Safety | * |
dc.language | English | * |
dc.publisher | Joe Bok Chung | * |
dc.subject | Helicobacter pylori | * |
dc.subject | Levofloxacin | * |
dc.subject | Third-line eradication | * |
dc.title | Efficacy of levofloxacin-based third-line therapy for the eradication of helicobacter pylori in peptic ulcer disease | * |
dc.type | Article | * |
dc.relation.issue | 2 | * |
dc.relation.volume | 11 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.index | KCI | * |
dc.relation.startpage | 226 | * |
dc.relation.lastpage | 231 | * |
dc.relation.journaltitle | Gut and Liver | * |
dc.identifier.doi | 10.5009/gnl16099 | * |
dc.identifier.wosid | WOS:000396641100008 | * |
dc.identifier.scopusid | 2-s2.0-85016992698 | * |
dc.author.google | Lim J.H. | * |
dc.author.google | Kim S.G. | * |
dc.author.google | Song J.H. | * |
dc.author.google | Hwang J.J. | * |
dc.author.google | Lee D.H. | * |
dc.author.google | Han J.P. | * |
dc.author.google | Hong S.J. | * |
dc.author.google | Kim J.H. | * |
dc.author.google | Jeon S.W. | * |
dc.author.google | Kim G.H. | * |
dc.author.google | Shim K.-N. | * |
dc.author.google | Shin W.G. | * |
dc.author.google | Kim T.H. | * |
dc.author.google | Kim S.M. | * |
dc.author.google | Chung I.-K. | * |
dc.author.google | Kim H.-S. | * |
dc.author.google | Kim H.U. | * |
dc.author.google | Lee J. | * |
dc.author.google | Kim J.G. | * |
dc.contributor.scopusid | 심기남(13604838300) | * |
dc.date.modifydate | 20240118163912 | * |